

accorded accession numbers HB11712 and HB11713. These deposits were made in accordance with the Budapest Treaty. Further, all restrictions as to the availability of these hybridoma cell lines will be irrevocably removed upon issuance of a patent to this application.--

IN THE CLAIMS:

Kindly cancel Claims 1-21 without prejudice and substitute the following claims in order to expedite prosecution:

-- 22. An anti-human gp39 (CD40L) antibody that is selected from the group consisting of 24-31, secreted by hybridoma 24-31, designated by ATCC Accession No. HB11712; 89-76, secreted by hybridoma 89-76 designated by ATCC Accession No. HB11713; and a monoclonal antibody that specifically inhibits the binding of either 89-76 or 24-31 to gp39 (CD40L).

23. The anti-human gp39 antibody of Claim 22 which is 89-76.

24. The anti-human gp39 antibody of Claim 22 which is 24-31.

25. A hybridoma 89-76 designated by ATCC Accession No. HB11713.

26. A hybridoma 24-31 designated by ATCC Accession No. HB11712.

27. A pharmaceutical composition containing an anti-human gp39 antibody according to Claim 22 and a pharmaceutically acceptable carrier.

28. The pharmaceutical composition of Claim 27 wherein the antibody contained therein is 89-76.